醫(yī)學(xué)資料 AHS淋巴瘤干細(xì)胞移植

自體造血干細(xì)胞移植治療

惡性淋巴瘤應(yīng)用進(jìn)展...IndicationsforHematopoieticStemCellTransplantsintheUnitedStates,2010

(Inflationfactor:Auto=1.25(80%),Allo=1.05(95%),AllTransplants)SUM12_28.pptSlide8NumberofTransplants.1.HL,霍奇金淋巴瘤中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.HL:ASCT綜合治療效果復(fù)發(fā)/耐藥：CR34-80%長(zhǎng)期生存率：25-50%

早期死亡率：4－21％復(fù)發(fā)/耐藥：10年生存率：50%10yPFS：45%10yRFS：23%首次復(fù)發(fā)：5年P(guān)FS30–52%,5年生存率：34－60％

.復(fù)發(fā)難治HL

PET/CT結(jié)果與自體移植的療效關(guān)系中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTERHaematologica2012PET/CT-PET/CT+.復(fù)發(fā)難治HD:不同預(yù)處理方案比較中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.1998-2009100ptsBuMelTt(busulfan,melphalan,thiotepa):60ptsOthers:40ptsCBV(21)TBICyE(14)BEAM(4)Melphalan(1)5yr-OS73%VS.44%5yr-PFS66%VS.37%NodifferencesintoxicityandNRMImprovedoutcomewithbusulfan,melphalanandthiotepaconditioninginAHSCTforrelapsed/refractoryHLTarunpreetB.Leukemia&Lymphoma,2014;55(3):583–587PFSOSP=0.03P=0.05.2.NHL,DLBCL彌漫大B淋巴瘤中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.復(fù)發(fā)NHL:自體移植是標(biāo)準(zhǔn)治療手段

PARMA隨機(jī)對(duì)照研究OSPFS.美羅華治療后復(fù)發(fā)：AHSCT價(jià)值，>2nd中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.Rituximab+DHAPandASCT

復(fù)發(fā)DLBCLEdoVellengaetal,blood,2008111:537-543DHAP 11273

40

19

9 R-DHAP 11376

55

31

14R-DHAPDHAPCumulativepercentageOverallsurvival.CORAL研究：

移植后療效EFSFailurefromdiagnosis=>=12monthsFailurefromdiagnosis>12monthsFailurefromdiagnosis=<12monthsStandardsalvageregimendoesnotovercomepoorprognosisofearlyrelapse.Rituximab-化療復(fù)發(fā)：自體移植的療效BrJHaematol.

2014Mar;164(5):668-74.有研究提示，美羅華化療后復(fù)發(fā)患者自體移植效果差？移植后5年

R+vsR-

PFS63%48%OS72%61%

美羅華治療后不會(huì)影響移植效果中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.彌漫大B淋巴瘤：一線中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.美羅華之前：ASHCTDLBCL1st中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTERAdvancesinHematology,2012意大利.DLBCL一線治療:

HDCT試驗(yàn)的薈萃分析Grebetal.,2007,CancerTreatRev.美羅華時(shí)代：自體移植療效，1st中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTERAdvancesinHematology,2012意大利.自體移植+/-rituximab治療

初治高危彌漫大BNHL，III期隨機(jī)對(duì)照OSEFSAnnalsofOncologyAdvanceAccesspublishedMay5,2010.Dose-denseandhigh-dosechemotherapyplusrituximab+ASHSCT

forprimarytreatmentofDLBCL

withapoorprognosis:aphaseIImulticenterstudyR-HDCHDCR-HDCHDChaematologica|2009;94(9)R-HDCHDCHDCR-HDC.SWOG-9704研究設(shè)計(jì)StiffP,etal.NEnglJMed2013;369(18):1681-1690.年齡:18-65歲aaIPI評(píng)分：2-3分主要終點(diǎn)：2年EFS，OS研究設(shè)計(jì)：253位患者接受5RCHOP21后隨機(jī)接受原方案3個(gè)療程的鞏固治療或者是自體移植做鞏固治療隨機(jī)化(n=253)對(duì)照組(n=128)移植組(n=125).SWOG-9704顯示：移植組較對(duì)照組

顯著延長(zhǎng)2年P(guān)FS，但是OS上無(wú)差別StiffP,etal.NEnglJMed2013;369(18):1681-1690.PFS(%)時(shí)間(年)對(duì)照組(n=128)2年P(guān)FS=55%移植組(n=125)2年P(guān)FS=69%P=0.005036902040608010012對(duì)照組(n=128)2年OS=71%移植組(n=125)2年OS=74%P=0.30036902040608010012時(shí)間(年)OS(%).SWOG-9704亞組分析顯示：移植組在aaIPI

為3分的患者中可以較對(duì)照組明顯延長(zhǎng)患者PFSStiffP,etal.NEnglJMed2013;369(18):1681-1690.aaIPI=2aaIPI=3中高危患者PFSPFS(%)時(shí)間(年)對(duì)照組2年P(guān)FS=63%移植組2年P(guān)FS=66%P=0.32高?；颊逷FS時(shí)間(年)對(duì)照組2年P(guān)FS=41%移植組2年P(guān)FS=75%P=0.001036912020406080100036912020406080100PFS(%).SWOG-9704亞組分析顯示：移植組在aaIPI

為3分的患者中可以較對(duì)照組明顯延長(zhǎng)患者OSStiffP,etal.NEnglJMed2013;369(18):1681-1690.aaIPI=2aaIPI=3中高?；颊逴S時(shí)間(年)高危患者OSOS(%)對(duì)照組2年OS=75%移植組2年OS=70%P=0.48對(duì)照組2年OS=64%移植組2年OS=82%P=0.01036912020406080100036912020406080100時(shí)間(年)OS(%).

原發(fā)中樞淋巴瘤：自體移植價(jià)值

HDAraC+VP16(CYVE)+HDCT(TT-BU-CY)

assalvagefor

relapse/resistantPCNSL2011updateN=60,medianFU5yOSchemosensitive97mchemoresistant18m

ICML2011Abstr.035Resp+HDCTNoResp+HDCTRespnoHDCTNOrespnoHDCT.中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER繼發(fā)中樞淋巴瘤移植效果好！.

化療敏感62%

vs不敏感36.2%Thiotepa,busulfanandcyclophosphamide+AHSCT，復(fù)發(fā)難治原發(fā)中樞淋巴瘤,5yOS

CR56.4%vs未CR31.1%Haematologica.

2012Nov;97(11):1751-6..AHSCT前CR/PR，移植后CR患者（5y-OS62%）AHSCT前SD/PD，移植后CR患者（5y-OS38.9%）移植后未獲得CR患者（5y-OS31.1%）Thiotepa,busulfanandCTX+AHSCTforrelapsedorrefractoryPCNSL/PLOTHaematologica.

2012Nov;97(11):1751-6..2000至2010年27例中位年齡:59歲中位

ECOG評(píng)分:276%DLBCL中位OS7月1年OS：62%自體移植治療淋巴瘤繼發(fā)中樞侵犯anInternationalPrimaryCNSLStudyGroupprojectJacolineE.haematol.2012.070839.ASCT：DLBCL臨床資料70例，中山大學(xué)腫瘤醫(yī)院2004.10-2013.3男性41例，女性29例中位年齡43歲（21-76歲）中位隨訪時(shí)間35.5月（0.4-94.2月）因腫瘤死亡29例,.DLBCLOS生存曲線中山大學(xué)腫瘤醫(yī)院1年OS91.0%,3年OS77.7%,5年OS56.9%.AHSCT：復(fù)發(fā)難治老年DLBCL

-日本血液學(xué)協(xié)會(huì)回顧性研究，2013ASH1993-2010年484pts中位64歲（60-78）中位隨訪26.5月移植相關(guān)死亡-4.1%(100天)-5.9%（1年）-10.7%3年）2年

PFS48%，OS58%60-64,65-69，>70歲，移植相關(guān)死亡無(wú)差異OS預(yù)后因素：>70歲，PS2-4分，移植前未CRBiolBloodMarrowTransplant.

2014Jan31..100d:4.1%1yr:5.9%2yr:7.7%3yr:10.7%復(fù)發(fā)難治老年彌漫大B淋巴瘤DLBCL:ANationwideRetrospectiveStudyDaiChihara.BiolBMT.20(2014)684-6891993to2010yearJapanSocietyforHCTdatabase484patientsmedianage:≥60years.Thecumulativeriskofrelapse1-yr:38.8%2-yr:45.5%3-yr:47.7%Multivariateanalysis≥70yPS2to4atASCTnotinremissionatASCTHigh-DoseChemotherapywithASCTforElderlyPatientswithRelapsed/RefractoryDLBCL:ANationwideRetrospectiveStudyDaiChihara.BiolBMT.20(2014)684-689.1-yr:55.9%2-yr:47.7%3-yr:40.6%1-yr:69.7%2-yr:57.9%3-yr:49.6%DaiChihara.BiolBMT.20(2014)684-689High-DoseChemotherapywithASCTforElderlyPatientswithRelapsed/RefractoryDLBCL:ANationwideRetrospectiveStudy.High-DoseChemotherapywithASCTforElderlyPatientswithRelapsed/RefractoryDLBCL:ANationwideRetrospectiveStudy2-yrOS60~6464.6%65~6950.6%≥70y45.7%DaiChihara.BiolBMT.20(2014)684-689.Zevaline+BEAM:DLBCL1stline

2011luganoabs256,GELA,法國(guó)

75DLBDL,R-CHOP/R-ABVCPIPI11;IPI227;IPI3-547F/U23m,2yEFS74%,2yOS80.5%PET+/-beforeAHSCT:same1toxicdeathpromisingwithacceptabletoxicity..Zevalin+BEAMvsBEAM→AHSCTfor

AggressiveLymphoma43CD20+pts

中位年齡55歲

病理類(lèi)型-DLBCL-transformedFLZevalin+BEAMN=22BEAM

N=21RAHSCTZ-BEAM

-Rituximab250mg/m2-Zevalin0.4mCi/kgd-14-Carmustine300mg/m2d-6

-Etoposide200mg/m2d-5--2

-Cytarabine200mg/m2Q12hd-5--2

-Melphalan140mg/m2

d-1Cancer.

2012Oct1;118(19):4706-14.2y-OS:91%VS62%(P=0.05)Zevalin+BEAMvsBEAM→AHSCTfor

AggressiveLymphoma2y-PFS:59%VS37%(P=0.2)Cancer.

2012Oct1;118(19):4706-14.23ptswithoutCRtosalvagechemotherapy6ptsRITcombinedwithHD-chemotherapy8ptsreceivedasequentialHD-chemotherapywithasecondASCTMyeloablativeAnti-CD20RIT±High-DoseChemotherapyFollowedbyASCTforRelapsed/RefractoryB-CellLymphomaResultsinExcellentLong-TermSurvivalWagnerJY.Oncotarget,June,Vol.4,No6.TheORR87%CR:64%MedianPFS47.5mMedianOS101.5monthsMyeloablativeAnti-CD20RIT±High-DoseChemotherapyFollowedbyASCTforRelapsed/RefractoryB-CellLymphomaResultsinExcellentLong-TermSurvivalWagnerJY.Oncotarget,June,Vol.4,No6.(A)OSaccordingtotreatmentmodality(B)PFSaccordingtotreatmentmodality(C)OSRITVS.RIT/HD-CTXorRIT/BEAM(D)PFSRITVS.RIT/HD-CTXorRIT/BEAMMyeloablativeAnti-CD20RIT±High-DoseChemotherapyFollowedbyASCTforRelapsed/RefractoryB-CellLymphomaResultsinExcellentLong-TermSurvivalWagnerJY.Oncotarget,June,Vol.4,No6.PhilippeA.JClinOncol31:4199-4206.

PD-1BlockadePidilizumab+AHSCT

DLBCLanInternationalPhaseIITrial66例30centersinUSA化療敏感復(fù)發(fā)，Chemotherapysensitive66pts

Pidilizumab(PD-1)1.5mg/kg×3,Q42d30to90dfromAHSCTAHSCTRestagedat30,44,and69w.OS(16m):85%PFS(16m):72%DisablingImmuneTolerancebyPD-1BlockadeWithPidilizumabAfterAHSCTforDLBCL:ResultsofanInternationalPhaseIITrialPFSandOSofalleligiblepatientsPFSandOSofthe24eligiblepatientswhoPET(+)aftersalvagetherapyPFS(16m):70%(PET+)72%(PET-)PhilippeA.JClinOncol31:4199-4206..3.PTCL-U外周Ｔ非特異性中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.復(fù)發(fā)耐藥T-NHL長(zhǎng)期隨訪結(jié)果，常規(guī)化療

N=45,總生存曲線黃慧強(qiáng)等，2007《癌癥》.ASCT治療外周T淋巴瘤：一線中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.ASCT外周T淋巴瘤：復(fù)發(fā)中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.T-NHL自體干細(xì)胞移植隨訪結(jié)果35例,中位隨訪23個(gè)月，預(yù)計(jì)中位總生存54個(gè)月，PTCL-U17.1%，LBL42.9%，ALCL20%，NK/T14.33%，皮下脂膜炎樣T5.7%1，3，5年OS為71%，59%，46%中山大學(xué)腫瘤醫(yī)院內(nèi)科.ASHCT治療T-NHL(一線/復(fù)發(fā))

2011luganoICML,abs100MDACC美國(guó)126例，49（18-75），初治33，

預(yù)處理：BEAM4年OS

PFS

CR18767

敏感復(fù)發(fā)3936

難治2415PTCLU4248ALCL4737NK/T667LBL14AHSCT考慮一線應(yīng)用

.AutoHSCTvs

alloHSCT

T-NHL:CIBMTRanalysis(1996–2006)自體，autoHCT(n=115)moreinALCL(53%vs.40%,p=0.04)lessadvanced:

CR1(35%

vs.14%,p=0.001),chemosensitivedisease(86%vs.60%,p<0.0001)2linespriortherapy(65%vs.44%,p<0.001)異基因，alloHCT(n=126,76matchedsiblings)100dTRM1yrOS3yrOS復(fù)發(fā)死亡

autoHCT2%62%53%73%alloHCT

17%52%41%44%SonaliSmith,etal.ASH2010,Abstract689..HematopoieticCellTransplantationforSystemicMatureT-CellNon-HodgkinLymphomaNRM:nonrelapsemortalitySonaliM.JClinOncol31:3100-3109.

241pts-ALCL(112)-PTCL-U(102)-AITL(27)≤60yrLinespriortotransplantation-?3(164)-≥3(73)

autoHCTN=115PrimaryoutcomesPFSNRMOS

alloHCTN=126.OSPFSNRMNRMPFSOSSonaliM.JClinOncol31:3100-3109.HematopoieticCellTransplantationforSystemicMatureT-CellNon-HodgkinLymphoma.PFSOSNRMPFSOSHematopoieticCellTransplantationforSystemicMatureT-CellNon-HodgkinLymphomaSonaliM.JClinOncol31:3100-3109..PCorradini.Leukemia(2014),1–7Intensifiedchemo-immunotherapy±SCTinnewlydiagnosedPTCL

AL:alemtuzumabHyperCHidam:-HD-MTX1.6g/m2d1,-CTX300mg/m2Q12hd1-3-HD-Ara-C2g/m2Q12hd1-3.PCorradini.Leukemia(2014),1–7

ClinAstudy-4yrOS49%-4yrPFS44%-4yrDFS65%Intensifiedchemo-immunotherapy±SCTinnewlydiagnosedPTCL.PCorradini.Leukemia(2014),1–7

ClinBstudy-4yrOS32%-4yrPFS26%-4yrDFS44%Intensifiedchemo-immunotherapy±SCTinnewlydiagnosedPTCL.晚期、復(fù)發(fā)NK/T淋巴瘤中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.，

自體外周血造血干細(xì)胞移植:NKT淋巴瘤，1st獲益患者CR、III-IV期預(yù)后不良

（kimHJ,etal.BoneMarrowTransplant.2006)

.自體移植:III/IV期和復(fù)發(fā)難治NK/TPromising3-yOS78.6%±13.9%3-yPFS63.6%±14.5%,Huanghui-qiang,

etalinpress中山大學(xué)腫瘤醫(yī)院SYSUCCP-Gemox

CR/PR自體移植.YDM,女，24歲，IVBNK/T

腹部巨大腫塊，PS=2腹腔腸道廣泛受累1療程后腸穿孔，人工肛，PEG-Gemox6療程，CRASCT后12個(gè)月CCR.UpfrontAutologuosStem-CellTransplantationinPeripheralT-CellLymphoma:NLG-T-015y-OS51%5y-PFS41%JClinOncol.

2013May1;31(13):1624-30.

.4.FL，

濾泡型淋巴瘤中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.RandomizedTrialsofUpfrontAutologousTransplantationforFLTrialMeasureTransplant,%Control,%PValueGOELAMS[1]9-yrPFS6439.004GLSG[2]5-yrPFS6236<.0001GELA[3]7-yrEFS3828.11GITMO/IIL[4]4-yrEFS6128<.0011.GyanE,etal.Blood.2009;113:995-1001.2.LenzG,etal.Blood.2004;104:2667-2674.

3.SebbanC,etal.Blood.2006;108:2540-2544.4.LadettoM,etal.Blood.2008;111:4004-4013.TrialOSTransplant,%Control,%PValueGOELAMS[1]9yrs7680.55GLSG[2]------GELA[3]7yrs7671.53GITMO/IIL[4]4yrs8180.96.

LongtermoutcomeofAHSCT

復(fù)發(fā)濾泡型248pts,age47(20-67)yMedianpriorchemotherapies2,110ptsAHSCTonlyMedianF/U6years(1-16)y47%progression13%diedwithoutNHL44%5YEFS63%5yOS2005ASCO,abstract6567JVoseetalUniversityofNebraskamedicalcenter.CUPtrial:PFS,1.00.80.60.40.20 0 12 24 36 48 60 72 84MonthsProportionprogression-free Events TotalChemotherapy 20 24Unpurged 9 22Purged 11 24SchoutenH,etal.JClinOncol2003;21:3918–27.TandemTransplantfor，雙移植

FollicularNHL<60y36ptsadvanced/recurrentFL;previouslyuntreated26.Treatment:

C2H2OP×2

Melphalan140mg/m2

CTX120mg/kg+TBICR(%)30.662.994.3MedianF/U86m.10yDFS60%10yOS83%Conclusion

--tandemtransplantissafeandcouldbecurativeforselectedFL--Nocorrelationbetweenmolecularandclinicalrelapse.

ChristiamRecher.France2003ASH.

研究流程復(fù)發(fā)FL:移植前利妥昔單抗凈化和/或移植后維持EBMT一項(xiàng)前瞻性研究,ASCTRuthP.JClinOncol31:1624-1630.10yrPFS:48.6%vs.42%(P=0.18)EffectonPFS10yrPFS:54%vs.37%(P=0.12)是否Rituximab凈化是否Rituximab維持RuthP.JClinOncol31:1624-1630復(fù)發(fā)FL:移植前利妥昔單抗凈化和/或移植后維持EBMT一項(xiàng)前瞻性研究,ASCT.SequentialtherapywithalternatingshortcoursesofR-chopandR-FMfollowedbyASCTresultsinlongtermremissioninadvancedFLEnricoD.bjh.2014.12894

10yrOS87%10yrPFS65%10yrOS(treatedatdiseaserelapse)70%10yrPFS(treatedatdiseaserelapse)60%.AuthorNF/UPFS(%)OS(%)Foran292952(48)50(102)Friedberg273646(60)58(60)Williams505930(60)37(60)Chen355231(60)37(60)移植后遠(yuǎn)期生存率：PFS:30-52%,OS37-58%ASCT:轉(zhuǎn)化濾泡型淋巴瘤

.轉(zhuǎn)化的惰性淋巴瘤:自體造血干細(xì)胞移植隨機(jī)對(duì)照

105pts

中位年齡：54歲

病理類(lèi)型：

DLBCL(102)1996-2009年50(48%)例接受AHSCT55(52%)例未接受AHSCTRAHSCTVP-16MephalanTBIIFRT30-35Gy(Bulkdisease)D.Villa.AnnalsofOncology24:1603–1609,2013.OverallSurvivalPrgression-FreeSurvivalASCTvs.NoASCTASCT(2005年后)vs.ASCT(2005年前)D.Villa.AnnalsofOncology24:1603–1609,2013轉(zhuǎn)化的惰性淋巴瘤:自體造血干細(xì)胞移植隨機(jī)對(duì)照.移植前加用rituximabVS.移植前未使用rituximabOverallSurvivalD.Villa.AnnalsofOncology24:1603–1609,2013轉(zhuǎn)化的惰性淋巴瘤:自體造血干細(xì)胞移植隨機(jī)對(duì)照.High-doseRIT++AHCTfor

poor-riskorrelapsedB-cellNHLNotransplant-relateddeath30(97%)ptsengraftedMedianfollow-upof21months(range1.4-43):

2-yearestimatedOS93%2-yearestimatedDFS80%ConclusionsThenovelHigh-doseRITwithZEVALIN+high-doseVP-16andCYiswelltoleratedandeffectiveinrefractoryB-cellNHL

.AutologousandAllogeneicSCTforTransformedFL:AReportoftheCanadianBMTJClinOncol.

2013Mar20;31(9):1164-71.

.雙移植auto-allotransplant復(fù)發(fā)難治濾泡BiolBloodMarrowTransplant.

2012Jun;18(6):951-7.27例，>3線隨訪39月,OS96%3年P(guān)FS96%中山大學(xué)腫瘤醫(yī)院SUNYAT-SENUNIVERSITYCANCERCENTER.5.套細(xì)胞淋巴瘤MCL,.1.套細(xì)胞淋巴瘤2008，2009

R-CHOP+AHSCT:R-CHOP+IFNPFSR-CHOP+AHSCTVSIFNPFS，R-CHOP+AHSCTVS

其他.年輕一線：MCL1vsMCL2.套細(xì)胞淋巴瘤長(zhǎng)期隨訪：MCL2方案.360例患者2000-2009年≥18歲Multivariateanalysis一項(xiàng)EBMT關(guān)于套細(xì)胞淋巴瘤移植后復(fù)發(fā)的預(yù)后因素和生存研究的回顧性分析S.Dietrich.AnnalsofOncology25:1053–1058,2014.MedianOS:19mRelapesd<12mvs.>12mS.Dietrich.AnnalsofOncology25:1053–1058,2014一項(xiàng)EBMT關(guān)于套細(xì)胞淋巴瘤移植后復(fù)發(fā)的預(yù)后因素和生存研究的回顧性分析.Firstlinevs.salvageSCTOSafterASCTfailurebytimingoffirstASCTOSafterASCTfailurebyrefractorydiseaseSensitivevs.refractoryS.Dietrich.AnnalsofOncology25:1053–1058,2014一項(xiàng)EBMT關(guān)于套細(xì)胞淋巴瘤移植后復(fù)發(fā)的預(yù)后因素和生存研究的回顧性分析.2000-2003年vs.2004-2007年OSafterASCTfailurebycalendaryearofrelapseOSfrom3month’slandmarkafterASCTfailurebyresponsetofirst-salvageregimengivenforrelapseCRvs.PRvs.SD/PDS.Dietrich.AnnalsofOncology25:1053–1058,2014一項(xiàng)EBMT關(guān)于套細(xì)胞淋巴瘤移植后復(fù)發(fā)的預(yù)后因素和生存研究的回顧性分析.NordicMCL3研究:90Y-ibritumomab-tiuxetanadded聯(lián)合BEAM/C治療移植前未CR的套細(xì)胞淋巴瘤ArneK.Blood.2014123:2953-2959

160pts

UntreatedStageII-IV<66yrMCL2×6R-maxi-CHOPR-HD-Ara-CRESPONDINGCRCRu/PRZevalin×11wbeforeASCTRituximab250mg/m2

1wbeforeandjustpriortoZevalinAHSCTBEAM/BEAC.EFSOSPFSSurvivalcurvesforMCL2andMCL3NordicMCL3研究:90Y-ibritumomab-tiuxetanadded聯(lián)合BEAM/C治療移植前未CR的套細(xì)胞淋巴瘤ArneK.Blood.2014123:2953-2959.移植前基于PET/CT掃描結(jié)果的生存曲線PFSOSNordicMCL3研究:90Y-ibritumomab-tiuxetanadded聯(lián)合BEAM/C治療移植前未CR的套